quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:45:00·107d
PRRelease
Salarius Pharmaceuticals Inc. logo

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics

SLRX· Salarius Pharmaceuticals Inc.
Health Care
Original source

Companies

  • SLRX
    Salarius Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Mar 11UpdateHC Wainwright & Co.$4.00
  • Aug 25UpdateHC Wainwright & Co.$5.00

Related

  • SEC104d
    SEC Form DEF 14A filed by Salarius Pharmaceuticals Inc.
  • SEC105d
    Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • SEC111d
    Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • INSIDER111d
    Director Hanish Arnold C sold $17 worth of shares (27 units at $0.64), closing all direct ownership in the company (SEC Form 4)
  • SEC111d
    SEC Form 8-K filed by Salarius Pharmaceuticals Inc.
  • SEC115d
    SEC Form PRE 14A filed by Salarius Pharmaceuticals Inc.
  • SEC125d
    SEC Form DEFA14A filed by Salarius Pharmaceuticals Inc.
  • SEC125d
    Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022